HR+/HER2- BREAST CANCER
Clinical trials for HR+/HER2- BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- BREAST CANCER trials appear
Sign up with your email to follow new studies for HR+/HER2- BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New dosing strategy aims to reduce side effects in breast cancer therapy
Disease control Not yet recruitingThis study tests whether starting abemaciclib at a lower dose and gradually increasing it can help patients with early high-risk HR+/HER2- breast cancer tolerate the drug better. The goal is to reduce side effects like diarrhea and fatigue, so more patients can complete their ful…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE4 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 26, 2026 05:05 UTC
-
Radiation plus Chemo-Immunotherapy shows promise in breast cancer trial
Disease control Not yet recruitingThis study tests whether adding a precise, high-dose form of radiation (SBRT) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a common type of breast cancer (HR+/HER2-). The trial will enroll 302 adults with high-risk features, such …
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new drug, BGB-43395, combined with letrozole against standard CDK4/6 inhibitor combinations for people with advanced or metastatic HR+/HER2- breast cancer who haven't had prior treatment for advanced disease. About 1056 participants will be randomly assigned to…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Could a genetic test spare young breast cancer patients from chemo?
Disease control Not yet recruitingThis study looks at whether a genetic test (Prosigna®) can help decide if younger women with a common type of early breast cancer need chemotherapy. About 3380 premenopausal women will be randomly assigned to either standard treatment (always chemo plus hormone therapy) or a test…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New hope for breast cancer patients with brain tumors: combining radiation and targeted drugs
Disease control Not yet recruitingThis study tests whether adding a targeted drug (dalpiciclib) and hormone therapy to brain radiation can help control breast cancer that has spread to the brain. About 46 women with HR-positive, HER2-negative advanced breast cancer will receive the combination treatment. The goal…
Matched conditions: HR+/HER2- BREAST CANCER
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 18, 2026 12:09 UTC